

Freedom of Information Request: 0530 2019/20

1. Within your health trust how many patients are currently [within the past 3 months] being treated with the following for breast cancer ?

Abemaciclib + aromatase inhibitor * - 0
 Abemaciclib + Fulvestrant - 17
 Alpelisib + Fulvestrant - 0
 Atezolizumab - 1
 Bevacizumab - 0
 Eribulin - 20
 Everolimus + Exemestane - 1
 Fulvestrant as a single agent - 5
 Gemcitabine + paclitaxel - 0
 Lapatinib - 0
 Neratinib - 0
 Olaparib - 0
 Palbociclib + aromatase inhibitor* - 0
 Pertuzumab + trastuzumab + docetaxel - 15
 Ribociclib + aromatase inhibitor* - 0
 Ribociclib + Fulvestrant - 0
 Talazoparib - 0
 Herceptin SC - 0
 Herceptin IV - 0
 Trastuzumab biosimilar SC -259
 Trastuzumab biosimilar IV - 13
 Trastuzumab emtansine - 52
 Other active systemic anti-cancer therapy ** - 47
 *aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole
 **eg. docetaxel, vinorelbine or capecitabine as a single agent

2. How many patients are being treated for

2a Neo-adjuvant breast cancer;

Trastuzumab total SC - 16

Trastuzumab total IV - 0

2.b Adjuvant breast cancer;

Trastuzumab total SC - 211

Trastuzumab total IV - 4

3. In the past 3 months, how many Urothelial cancer patients were treated with;

Clarification from requestor

it would be: Urothelial cancers encompass carcinomas of the bladder, ureters and renal pelvis

Atezolizumab - 0

Carboplatinum in combination with another agent - 0

Carboplatinum single agent - 0

Cisplatinum in combination with another agent - 0

Cisplatinum single agent - 0

Nivolumab - 0

Pembrolizumab - 0

Any other chemo regimen without cisplatinum or carboplatinum - 0

Other active systemic anti-cancer therapy [please state] - 0

Palliative care only - 0